Chinese Journal of Pharmacovigilance ›› 2015, Vol. 12 ›› Issue (4): 254-256.
Received:2014-06-19
Revised:2015-07-27
Online:2015-04-08
Published:2015-07-27
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
| [1] 彭卫生,王英年,肖成志.新编结核病学[M].北京：中国医药科技出版社，2003:426. [2] 崔淑艳，李书彦，李梦杰.垂体后叶素治疗咯血发生严重低钠脑病5例的原因分析及辩证施护[J].中国临床研究,2011,3(11)：92-93． [3] 张运剑，刘春萍，张伟华,等. 垂体后叶素致抗利尿激素分泌不当综合征89例的回顾性分析[J].药物不良反应杂志，2009,11（1）：5-8. [4] 陈艺坛,陈志斌,陈光,等.垂体后叶素致SIADH的临床研究[J].临床肺科杂志,2006,5(11):640. [5] 王利民,周建英.垂体后叶素治疗咯血副作用267例[J].浙江医学,2007, 29(2):188-190. [6] 吕聪燕. 垂体后叶素治疗大咯血致低钠性脑病的护理[J].护士进修杂志，2012,27（8）：756-757. [7] 李军利，禹春玲，卢春玲,等. 垂体后叶素治疗咯血致低钠血症12例分析[J].临床肺科杂志，2012,17（8）：1385-1386. [8] 许慧阳，侯为顺.血钠水平在肝硬化中的临床意义[J].实用全科医学，2006,4（3）：278-279. [9] 刘保东.药品说明书缺陷致垂体后叶注射液严重不良反应1例[J].中国医院药学杂志，2012,32（5）：398-399. [10] 梁颖，米玉红，刘双.垂体后叶素对咯血患者血钠影响的临床分析[J].药物不良反应杂志，2010,12（6）：393-396. |
| [1] | ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913. |
| [2] | QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727. |
| [3] | LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785. |
| [4] | ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789. |
| [5] | LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793. |
| [6] | LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569. |
| [7] | YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281. |
| [8] | LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285. |
| [9] | ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192. |
| [10] | LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42. |
| [11] | SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414. |
| [12] | ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024. |
| [13] | YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028. |
| [14] | SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899. |
| [15] | WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
